Stay updated with breaking news from Gene Therapy Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ECUR-506 is a gene editing-based investigational therapy for the treatment of Ornithine Transcarbamylase (OTC) deficiency
VANCOUVER, BC, Dec. 4, 2023 /PRNewswire/ - PreveCeutical Medical Inc. , is pleased to announce that it has started preparations to accelerate completion of its preclinical dual gene therapy...
A podcast, Netflix series, and TV adaptation examine regenerative medicine doctor's wrongdoings
PHILADELPHIA, Nov. 17, 2023 -- Passage Bio, Inc. , a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced...
On track to present initial safety and biomarker data from three Cohort 1 patients in global Phase 1/2 upliFT-D trial of PBFT02 for the treatment ...